PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver cirrhosis |
| Symptom | C0948807|hepatic impairment |
| Sentences | 2 |
| PubMedID- 25860376 | The pharmacokinetics of macitentan, act-132577, and act-373898 were studied after administration of a single dose of macitentan 10 mg to subjects with mild, moderate, and severe hepatic impairment due to liver cirrhosis in a single-center, open-label design. |
| PubMedID- 23955175 | This study was an open-label, single-dose, parallel-design, multi-center study involving subjects who were categorized into four groups by their hepatic function, as defined by the child–pugh criteria : normal hepatic function, hepatic impairment due to liver cirrhosis classified as mild (child-pugh a), hepatic impairment due to liver cirrhosis classified as moderate (child-pugh b), and hepatic impairment due to liver cirrhosis classified as severe (child-pugh c). |
Page: 1